Important Information for Investors: Securities Class Action Lawsuit Against Pacira BioSciences, Inc.
On March 4, 2025, Kahn Swick & Foti, LLC (“KSF”) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., announced that they are reminding investors of the upcoming deadline to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (PCRX). The lawsuit alleges that the Company and certain of its executives made false and misleading statements and failed to disclose material information during the Class Period, which spans from August 2, 2023, to August 8, 2024.
Background of the Lawsuit
According to the complaint, the defendants made false and/or misleading statements and/or failed to disclose that:
- There were issues with Pacira’s EXPAREL (bupivacaine liposome injection) product;
- The Company was experiencing manufacturing issues with EXPAREL;
- The Company’s financial statements were not accurate;
- The Company was under investigation by the U.S. Securities and Exchange Commission;
As a result of these allegedly false and misleading statements, Pacira’s stock traded at artificially inflated prices during the Class Period.
Impact on Individual Investors
If you purchased Pacira BioSciences securities during the Class Period, you may be able to recover your losses by serving as a lead plaintiff in this class action lawsuit. The lead plaintiff is a court-appointed representative who acts on behalf of all members of the class. As a lead plaintiff, you may be entitled to a larger share of any recovery.
To be eligible to serve as a lead plaintiff, you must meet certain requirements. You must be a member of the class, and you must be willing and able to cooperate with the class counsel in the pursuit of the action. If you wish to apply to serve as a lead plaintiff, you must file your motion no later than March 14, 2025.
Impact on the World
The securities class action lawsuit against Pacira BioSciences, Inc. is significant for several reasons:
- It highlights the importance of accurate financial reporting and disclosure.
- It underscores the need for companies to be transparent about any issues that may impact their financial performance.
- It serves as a reminder that investors have legal recourse when companies make false or misleading statements.
Moreover, the outcome of this lawsuit could have far-reaching implications for the securities industry as a whole. If the plaintiffs are successful, it could lead to increased scrutiny of financial reporting practices and potentially lead to more stringent regulations.
Conclusion
If you purchased Pacira BioSciences securities during the Class Period, you may be able to recover your losses by serving as a lead plaintiff in the securities class action lawsuit against the Company. The deadline to file your motion is March 14, 2025. The lawsuit alleges that the Company and certain executives made false and misleading statements and failed to disclose material information during the Class Period, leading to artificially inflated stock prices.
The outcome of this lawsuit could have significant implications for the securities industry, highlighting the importance of accurate financial reporting and disclosure. It serves as a reminder that investors have legal recourse when companies make false or misleading statements. If you have any questions or would like more information, please do not hesitate to contact KSF.
The information provided in this blog post is for informational purposes only and should not be considered legal advice. Please consult with a securities attorney or financial advisor for further information.
